Definium Therapeutics (NASDAQ:DFTX) Stock Price Up 8.3% – Still a Buy?

Definium Therapeutics, Inc. (NASDAQ:DFTX) shares were up 8.3% during trading on Tuesday . The stock traded as high as $17.22 and last traded at $17.06. Approximately 1,438,534 shares changed hands during mid-day trading, a decline of 27% from the average daily volume of 1,983,315 shares. The stock had previously closed at $15.75.

Analyst Upgrades and Downgrades

DFTX has been the subject of a number of recent research reports. Chardan Capital upgraded Definium Therapeutics to a “strong-buy” rating in a report on Wednesday, November 19th. Royal Bank Of Canada lifted their price objective on shares of Definium Therapeutics from $20.00 to $36.00 and gave the stock an “outperform” rating in a research note on Friday, January 23rd. Jefferies Financial Group started coverage on shares of Definium Therapeutics in a research report on Thursday, January 29th. They set a “buy” rating and a $30.00 price objective on the stock. Robert W. Baird set a $37.00 target price on shares of Definium Therapeutics in a report on Thursday, January 29th. Finally, JonesTrading started coverage on shares of Definium Therapeutics in a report on Tuesday, December 23rd. They set a “buy” rating and a $61.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $35.22.

Definium Therapeutics Trading Up 7.3%

The stock’s 50-day moving average price is $14.79 and its 200 day moving average price is $12.36. The company has a debt-to-equity ratio of 0.31, a current ratio of 3.30 and a quick ratio of 3.30. The firm has a market capitalization of $1.66 billion, a PE ratio of -8.28 and a beta of 2.57.

Insider Transactions at Definium Therapeutics

In related news, insider Mark Sullivan sold 11,276 shares of the business’s stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $148,279.40. Following the completion of the transaction, the insider owned 282,576 shares of the company’s stock, valued at $3,715,874.40. The trade was a 3.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Robert Barrow sold 25,791 shares of the company’s stock in a transaction on Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $339,151.65. Following the sale, the chief executive officer owned 778,477 shares of the company’s stock, valued at approximately $10,236,972.55. This represents a 3.21% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 42,667 shares of company stock valued at $561,071. 2.26% of the stock is currently owned by corporate insiders.

Institutional Trading of Definium Therapeutics

Several hedge funds have recently modified their holdings of DFTX. Russell Investments Group Ltd. increased its stake in shares of Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after acquiring an additional 2,003 shares during the period. BIT Capital GmbH acquired a new stake in Definium Therapeutics during the 3rd quarter worth about $26,000. CWM LLC grew its position in Definium Therapeutics by 67.4% during the 2nd quarter. CWM LLC now owns 4,459 shares of the company’s stock worth $29,000 after purchasing an additional 1,796 shares during the period. Fifth Third Bancorp raised its stake in shares of Definium Therapeutics by 5,593.2% during the 3rd quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock valued at $40,000 after buying an additional 3,300 shares during the last quarter. Finally, Sound Income Strategies LLC acquired a new position in shares of Definium Therapeutics in the 3rd quarter valued at about $46,000. 27.91% of the stock is owned by hedge funds and other institutional investors.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.